Erasca (ERAS) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 470.6% versus a loss of 1.1%. Over five years, PTCT leads with a +66.0% price change compared with -20.7% for ERAS. PTC Therapeutics is the larger company by market cap ($5.28 billion vs $4.94 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | PTCT |
|---|---|---|
| Share price | $14.12 | $63.23 |
| Market cap | $4.94B | $5.28B |
| 1-day change | -1.26% | -0.74% |
| YTD return | +280.38% | -16.76% |
| 1-year return | +470.56% | -1.06% |
| 5-year return | -20.67% | +66.00% |
| Forward P/E | — | 23.62 |
| EPS (TTM) | $-0.95 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-124.55M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $24.28 | $90.87 |
| 52-week low | $2.11 | $61.23 |
| Distance from 52-week high | -41.85% | -30.42% |
| Analyst consensus | none | buy |
| Avg. price target upside | +70.75% | +60.98% |
| Average volume | 4.29M | 1.15M |
| Shares outstanding | 349.76M | 83.46M |
| Employees | 103 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed PTCT by 471.6 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
ERAS vs PTCT FAQ
Which is bigger, Erasca or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.28B compared with $4.94B for Erasca (ERAS).
Which stock has performed better over the past year, ERAS or PTCT?
ERAS returned +470.56% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.